Newborn dried blood spots are created when a few drops of blood are placed on a small filter-paper card and allowed to dry. For decades, these samples have been used to screen infants for metabolic, endocrine and genetic disorders. Because the cards are inexpensive to store and can preserve DNA for years, scientists have increasingly viewed them as a potential resource for population-scale genomic research. The new study examines whether the same material could reveal germline mutations—genetic changes present in nearly every cell of the body—that predispose children to cancer.

Childhood cancer predisposition syndromes are uncommon, but their consequences can be profound. A pathogenic variant inherited from a parent, or arising very early in embryonic development, can substantially increase the probability of developing leukemia, a brain tumor, a kidney tumor, a sarcoma or another pediatric cancer. In some syndromes, tumors appear during infancy or early childhood, often before symptoms become obvious. Detecting a predisposition before disease develops could allow doctors to begin surveillance earlier, use imaging or laboratory tests selectively, and recognize suspicious symptoms at a stage when treatment may be more effective.

The study’s central scientific challenge is analytical rather than merely logistical. Dried blood spots contain a limited amount of biological material, and the DNA may be fragmented or chemically altered by storage conditions. Researchers must extract usable genetic material, sequence selected regions or the broader genome, and distinguish genuine disease-associated variants from technical artifacts. This requires rigorous quality control, validation and interpretation using clinical databases and established classification systems. A sequence difference is not automatically a mutation that causes cancer; its significance depends on the gene involved, the exact molecular change, available population data and evidence from affected families.

A population-based strategy could also change how predisposition is discovered. Current genetic testing is frequently triggered by family history, a child’s diagnosis or a recognizable pattern of tumors. That approach can miss children whose families have no known cancer history, particularly when a variant is new, inherited from an unaffected relative or associated with incomplete penetrance. Screening newborn samples could identify risk before a family has any reason to suspect a hereditary syndrome. In principle, this would shift cancer prevention from a reactive model—testing after warning signs emerge—to a proactive model based on an individual’s biological risk.

Yet the promise of early detection must be balanced against the complexity of predicting cancer. Not every child carrying a predisposition variant will develop a tumor, and the age of onset can vary widely. Some genetic changes are associated with a broad spectrum of outcomes rather than one specific cancer. A result may therefore indicate increased susceptibility without providing a precise forecast. Communicating that uncertainty to parents would require specialist genetic counseling, clear explanations of absolute and relative risk, and carefully designed surveillance plans. Without that support, genomic information could generate anxiety, unnecessary procedures or a false sense of security.

The use of newborn blood spots also raises questions about consent and public trust. In many health systems, samples are collected as part of routine screening, while their later research use may be governed by separate policies. Families may differ in whether they want their child’s sample analyzed for conditions that were not part of the original newborn program. Any expansion toward cancer predisposition screening would need transparent rules covering permission, the return of results, storage duration, withdrawal options and access to genetic counseling. The security of genomic data would be equally important because a predisposition result can affect not only the child but also biological relatives.

Technical performance will determine whether this concept can move from research into clinical practice. A useful screening program must achieve high analytical sensitivity without producing an unmanageable number of false-positive findings. It must also be able to identify different classes of variants, including single-nucleotide changes, small insertions and deletions, and potentially larger structural alterations. Confirmatory testing from a fresh blood sample would be essential before any medical decision was made. The study therefore speaks to a broader development in genomics: the effort to build testing systems that are sufficiently accurate, scalable and clinically interpretable for entire populations rather than selected high-risk families.

The potential impact extends beyond individual diagnoses. If newborn genomic screening reliably identifies children at elevated risk, health services could study how surveillance changes tumor stage, treatment intensity, survival and quality of life. It could also reveal how often cancer-predisposition variants occur in the general population, including communities historically underrepresented in genetic research. At the same time, such programs could expose inequalities if follow-up care is available only to families with specialist centers, transportation, insurance coverage or the resources to navigate complex medical systems. A genetic result is useful only when the healthcare system can respond to it.

Diller, Cherkerzian, Cinelli and colleagues present dried blood spots as a bridge between established newborn screening and the expanding capabilities of genomic medicine. Their work does not make childhood cancer predictable in a simple, deterministic sense. Instead, it explores whether a tiny blood sample collected at the beginning of life can provide clinically meaningful information about inherited vulnerability long before cancer appears. The next steps will involve independent validation, long-term follow-up and careful evaluation of benefits, harms and cost. If those challenges can be met, the humble newborn blood-spot card could evolve from a tool for detecting rare biochemical disorders into an early genomic signal for preventing some of the most devastating diseases of childhood.

Subject of Research: Population-based genomic detection of inherited childhood cancer predisposition using newborn dried blood spots.

Article Title: Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots.

Article References: Diller, L., Cherkerzian, S., Cinelli, A.E. et al. “Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots.” Nature Communications 17, 8183 (2026). https://doi.org/10.1038/s41467-026-76296-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-76296-8

Keywords: childhood cancer, cancer predisposition, newborn screening, dried blood spots, genomic medicine, germline variants, genetic testing, early detection, pediatric oncology, precision medicine

The PGR study corroborated previously established phenotypic associations for numerous homLoF variants. For instance, homozygous LoF mutations in LDLR were linked to hypercholesterolemia, while variants in LPL were associated with elevated triglyceride levels. Similarly, ANGPTL3 and APOB homLoF carriers exhibited notably reduced cholesterol and triglyceride profiles, whereas variants in ADCY3, POMC, MC4R, and MRAP2 were implicated in obesity phenotypes. These observations not only validate the penetrance of key metabolic genes but also affirm the rigorous phenotyping framework employed by the PGR.

Delving into therapeutically relevant homLoF variants, the study sheds light on the nuanced interplay between genotype and phenotype in neurodegeneration. LRRK2, a well-known protein kinase whose gain-of-function variants increase Parkinson’s disease risk, was examined in the context of loss-of-function. Notably, two PGR participants harboring homozygous LRRK2 pLoF variants exhibited early-stage kidney disease, a phenotype absent in heterozygous carriers. This human evidence mirrors renal dysfunction observed in LRRK2 knockout rodent models and preclinical trials with LRRK2 inhibitors in primates, suggesting a need for vigilant renal monitoring in therapeutic contexts targeting LRRK2.

In the realm of metabolic disease, a participant with a homLoF variant in SLC2A4—the gene encoding GLUT4—demonstrated type 2 diabetes, aligning with experimental models where GLUT4 deficiency impairs glucose homeostasis. Contrastingly, homLoF variants in DENND1B, previously linked to obesity and implicated in MC4R signaling pathways, did not confer obesity phenotypes in the cohort. This could indicate a lack of functional penetrance of DENND1B in human energy balance, differing substantially from prior murine models. Moreover, carriers of homLoF mutations in POMC, MC4R, and MRAP2 exhibited elevated BMI, reinforcing their contributory role to obesity.

Cardiovascular research insights emerged with RXFP1, a gene encoding a receptor extensively studied for its role in fertility, fibrosis, and cardiac function. Despite the gene’s pivotal role in murine reproductive and cardiovascular models—where its absence causes pronounced phenotypes—16 PGR individuals with RXFP1 homLoF variants spanned ages 30 to 73 years with no consistent deficits. Subtle associations with reduced waist-to-hip ratio and myocardial infarction risk were noted, and echocardiographic evaluations revealed mild variations in cardiac function among some homozygotes. Such findings suggest that the translational relevance of RXFP1 as a therapeutic target may be overestimated from rodent data, urging a recalibration of expectations for RXFP1 agonist therapies.

The hepatoprotective potential of CIDEB inhibition also gained support from PGR findings. Fourteen individuals homozygous for CIDEB loss-of-function variants displayed no liver disease, and burden analyses correlated CIDEB deficiency with decreased levels of liver enzymes ALT and AST and a reduced risk of non-alcoholic fatty liver disease. This human genetic evidence bolsters the rationale for targeting CIDEB therapeutically with siRNA or other modalities, highlighting an encouraging safety profile for chronic intervention.

Surprising evolutionary biology insights were uncovered in the reproductive gene PRDM9, a histone methyltransferase essential for meiotic recombination hotspot determination. While Prdm9 knockout mice exhibit infertility, PGR identified multiple human homLoF variant carriers of PRDM9 with proven fertility and successful reproduction. This stark species divergence reveals that PRDM9’s indispensability in meiosis is not conserved in humans, emphasizing the complexity of translating mouse genetic models to human biology.

Sensory gene analyses revealed functionally impactful homLoF mutations in TRPM8, an ion channel activated by cold stimuli. RBG cohort phenotyping demonstrated that carriers exhibited delayed cold-induced pain sensitivity and increased tolerance to cold-related discomfort, aligning with murine knockout models. Intriguingly, genome-wide association studies link TRPM8 variants to migraine susceptibility, positing TRPM8 inhibition as a promising therapeutic avenue. The PGR data indicate that complete loss of TRPM8 is generally well-tolerated, mitigating safety concerns for pharmacological antagonism targeting migraine prevention.

Collectively, these results highlight the critical importance of integrating large-scale human genomic data with functional assays to delineate gene-disease relationships and therapeutic potential. The PGR exemplifies how comprehensive population-based sequencing can validate, refine, or refute biological assumptions derived from animal models, fostering a more precise paradigm for drug target validation. By profiling rare homLoF variants and linking them with detailed phenotypic data, the study provides invaluable resources for developing safer, more effective genetic-driven therapies.

This study also accentuates the value of consanguineous populations, such as the Pakistani cohort, which enrich for homozygous rare variants and enable the detection of recessive phenotypes difficult to observe in outbred populations. Such datasets maximize the discovery power for identifying natural human knockouts, thereby informing on both the efficacy and potential deleterious effects of gene inactivation.

Beyond specific gene findings, the broader implication is a caution against uncritical extrapolation from model organisms to human physiology. While murine models remain indispensable, discrepancies evidenced in PRDM9 and RXFP1 underscore that human genetic data are indispensable for accurate target validation and safety assessment. This alignment between genotype, phenotype, and therapeutic action forms the cornerstone of precision medicine.

As the PGR and similar initiatives continue to expand, the integration of genomics with phenotypic and clinical data will catalyze a new era of therapeutic development truly grounded in human biology. The promise of harnessing human loss-of-function variants lies not only in uncovering disease mechanisms but also in guiding drug discovery toward targets with validated human safety and efficacy profiles, ultimately accelerating the path from bench to bedside.

This landmark study published in Nature offers a crucial template for leveraging population genomics in drug development, emphasizing the necessity of human genetic evidence to underpin the next generation of therapies. The insights gleaned provide a roadmap for more rational, genetics-informed clinical decision-making, heralding a future where personalized medicine and pharmacogenomics converge to transform healthcare.

Subject of Research: Genomic analysis of homozygous loss-of-function variants in the Pakistan Genome Resource and their implications for human disease and drug target validation.

Article Title: Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource.

Article References:
Koch, C., Khalid, S., Khan, M.Z. et al. Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource. Nature (2026). https://doi.org/10.1038/s41586-026-10667-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10667-5

The newly published research scrutinizes penetrance—the probability that a person carrying a specific genetic variant will actually develop the associated disease—in the context of genomic screening applied to newborns. Historically, estimates of penetrance have been derived largely from studies on individuals already manifesting disease symptoms or with family histories signifying high genetic risk. This methodological bias inflates perceived risk levels, leading to exaggerated assumptions about how likely a variant is to cause illness across the general population. The Exeter research team’s analysis, made possible by unprecedented access to vast population cohorts including nearly one million participants from sources such as the UK Biobank and the All of Us Research Program, aims to recalibrate these risk estimates by examining genetic variants in a far broader and more representative population.

Focusing on a curated set of over 50 genes implicated in 15 conditions prioritized for newborn genome screening trials, researchers queried the presence of particular variants previously medically classified as pathogenic. Their systematic interrogation revealed a consistent but notably weaker association between these variants and disease than previously reported in clinical or familial studies. Specifically, for many pathogenic variants, the penetrance within the general population was significantly lower, indicating that carrying the variant does not guarantee disease occurrence. These findings challenge existing paradigms in genetic screening and call for nuanced interpretation of genetic data in preventive health contexts.

One of the critical insights from the Exeter group’s research is the delineation of risk patterns tied to the mode of genetic inheritance. Conditions arising from the loss of function in just one copy of a gene (heterozygous loss-of-function variants) appear to have a higher propensity for overdiagnosis when used as biomarkers in newborn screening. Conversely, diseases requiring two defective copies to manifest (homozygous loss-of-function variants) tend to show lower rates of overdiagnosis risks in population-based assessments. This distinction is pivotal in refining screening protocols that balance sensitivity with specificity, aiming to avoid psychological and medical ramifications for families inadvertently labeled at high risk due to misestimated penetrance.

The implications of this research are profound, given the global momentum toward newborn whole-genome sequencing as a preventative health measure. The UK, in particular, is emerging as a leader in piloting such programs, sparking intense international interest and debate. As Professor Caroline Wright from the University of Exeter Medical School emphasizes, the stakes for families are enormous. Receiving information that a newborn may carry high-risk genetic markers can provoke profound anxiety and initiate cascades of medical intervention—often without clear evidence of benefit. Ensuring that risk estimates reflect real-world penetrance derived from unbiased cohorts is therefore essential to safeguard families from unnecessary distress and medical procedures.

A major challenge highlighted by the study is the gap between genetic discoveries made in clinical settings versus their application in public health screening. The current genetic risk models are often based on cohorts enriched for disease presence or familial predisposition, which do not capture the full spectrum of genetic expression in the wider population. By leveraging large biobanks representative of general populations, the Exeter research enables a recalibration of these models that can better inform public health policies on newborn screening. This recalibration has the potential to transform genomic medicine, moving it from a reactive clinical tool to a truly predictive and preventive platform with minimal harm.

Further complicating the picture are the diverse disease mechanisms and inheritance patterns encountered across the gene variants studied. For some conditions, penetrance appears to be incomplete or influenced by additional genetic, epigenetic, or environmental factors not captured by simple variant presence. This biological complexity demands a more sophisticated analytic approach capable of integrating multiparameter data—something the current research initiative is actively pursuing through subsequent studies. Such integrative analyses hold the promise of tailoring newborn screening to individual risk profiles rather than broad categorical designations, ushering in a new era of precision public health genomics.

In tandem with these penetrating genetic insights, the research group has published a series of influential papers in the European Journal of Human Genetics and via preprint servers such as medRxiv, expanding the scientific community’s understanding of variant penetrance across clinically relevant genes including COL1A1/2 linked to osteogenesis imperfecta, TSC1/TSC2 associated with tuberous sclerosis complex, as well as genes involved in heritable retinoblastoma and severe combined immunodeficiency. Each paper systematically quantifies population-level penetrance, highlighting discrepancies with prior clinical data and underscoring the need for robust evidence before policy implementation.

This body of work represents a paradigm shift in the conceptual framework underpinning genomic newborn screening. It signals a move towards a more cautious and evidence-based approach where the risks and benefits of detecting genetic predispositions are carefully balanced against the psychological, social, and medical consequences faced by families. Given the rapid technological advances that have made whole-genome sequencing accessible, this research functions as a critical counterbalance, emphasizing that scientific innovation must be tempered with rigorous population-level validation.

Looking forward, the Exeter team advocates for intensified research efforts incorporating even larger and more diverse population datasets, coupled with longitudinal follow-ups to observe actual disease manifestation over time in variant carriers. This longitudinal perspective is indispensable to strengthening penetrance estimates and refining screening guidelines. Moreover, the integration of environmental and lifestyle factors into genetic risk models promises to further sharpen predictive accuracy, transforming newborn genome screening into a precision tool optimized for public health impact.

As genomic medicine marches towards routine neonatal application, the Exeter-led studies serve as a clarion call to stakeholders from clinicians and genetic counselors to policymakers and advocacy groups. The message is clear: newborn genome screening holds transformative promise but must be implemented with precision, caution, and compassion, founded on comprehensive population evidence to mitigate harms from overdiagnosis and undue parental stress. Only by grounding genomic screening in robust epidemiological data can we unlock its full potential to revolutionize early intervention for inherited diseases.

This research, funded by the Medical Research Council and the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre, sets a new benchmark for scholarly rigor and public health responsibility in the age of genomics. As countries like the UK pioneer pilot newborn screening programs, the scientific community will be watching closely to ensure that the future of genomic medicine is not just technological but also ethically sound and clinically meaningful.

In conclusion, the University of Exeter team’s investigations compel a reevaluation of the penetrance associated with genetic variants previously considered highly pathogenic when extrapolated beyond disease-enriched cohorts. Their work highlights an essential intersection of genetics, epidemiology, and public health, emphasizing the need for cautious translation of genomic screening from research into clinical birth settings. By charting a course toward more accurate, population-tailored risk assessments, these studies pave the way for responsible integration of genomics into newborn care that maximizes benefit while minimizing harm.

Subject of Research: People

Article Title: Revisiting penetrance in an era of genomic screening

News Publication Date: 21-Apr-2026

Keywords: Genetic screening, Medical genetics, Preventive medicine, Clinical medicine, Genetic disorders, Genetic testing